Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41409-018-0178-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Extemporaneous Topical Minoxidil Solutions for the Treatment of Androgenetic Alopecia- Stability Studies and Incorporation Tests of Active Pharmaceutical Ingredients in Aloplus Total Base.
Int J Pharm Compd
February 2024
Department of Pharmacy - Pharmaceutical Sciences, University of Bari "Aldo Moro", Bari, Italy.
Minoxidil is one of the most employed active pharmaceutical ingredients for the treatment of androgenetic alopecia. The authors propose a new method for production of minoxidil lotions using Aloplus Total. The latter is a propylene glycol-free liquid base in which the presence of hydroxypropyl-ß-cyclodextrin and ethanol allows the solubilization of high drug amounts.
View Article and Find Full Text PDFEfficacy, Tolerability, and Superiority of Propylene Glycol-Free, North American Witch-Hazel ()-Based Solution of 5% Minoxidil Sulfate for the Treatment of Female Androgenetic Alopecia.
Int J Trichology
December 2023
Center for Dermatology and Hair Diseases Professor Trüeb, Zurich-Wallisellen, Switzerland.
Background: Androgenetic alopecia leads to progressive hair loss in susceptible individuals if left untreated. Topical minoxidil represents an evidence-based treatment for female androgenetic alopecia, though with variable success.
Aims And Objectives: Treatment of minoxidil non-responders remains challenging, as does treatment of patients with propylene glycol sensitivity or irritable scalp syndrome.
Optimizing high dose melphalan.
Blood Rev
March 2024
Adult BMT Service Memorial Sloan Kettering Cancer Center, 530 East 74th Street, New York, NY 10021, United States of America. Electronic address:
Melphalan, has been a major component of myeloma therapy since the 1950s. In the context of hematopoietic cell transplantation (HCT), high dose melphalan (HDM) is the most common conditioning regimen used due to its potent anti-myeloma effects and manageable toxicities. Common toxicities associated with HDM include myelosuppression, gastrointestinal issues, and mucositis.
View Article and Find Full Text PDFSafety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study.
Transplant Cell Ther
November 2023
Section of Hematology and Medical Oncology, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts; Stem Cell Transplant Program of Section of Hematology and Oncology, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts; Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts. Electronic address:
Patients with systemic light chain (AL) amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation (HDM/SCT) may develop renal and cardiac toxicities potentially exacerbated by the co-solvent propylene glycol in conventional melphalan formulations. We investigated the safety and efficacy of propylene glycol-free melphalan (PGF-Mel) during HDM/SCT in patients with AL amyloidosis (ClinicalTrials.gov identifier NCT02994784).
View Article and Find Full Text PDFEfficacy of a prolonged stability melphalan formulation for intra-arterial treatment of retinoblastoma.
J Neurointerv Surg
May 2024
Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona, USA
Background: Melphalan, which is poorly soluble at room temperature, is widely used for the treatment of retinoblastoma by selective ophthalmic artery infusion. Evomela, a propylene glycol-free formulation of melphalan with improved solubility and stability, has recently been used as an alternative.To compare the safety and efficacy of Evomela with standard-formulation melphalan (SFM) in the treatment of retinoblastoma by selective ophthalmic artery infusion.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!